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ABSTRACT
The objective of this study was to evaluate the efficacy of multi-micronutrients (MMN)
supplementation during preconception period on improving fetal survival and concentration of
umbilical cord Insulin-like Growth Factor 1 (IGF-1). A randomized double blind community based
trial had been conducted. Study subjects were randomly assigned into two groups (n = 210 in each
group), namely multi-micronutrient group (MMN group) and  placebo-iron  folic  acid  group
(Placebo-IFA  group).   The   MMN   group   received   capsule   of  multi-micronutrients  containing
15 micronutrients every 2 days during preconception period (2-6 months before pregnancy) and to
be continued with daily dose during pregnancy. Placebo-IFA group received placebo capsule every
2 days during preconception period (2-6 months before pregnancy) and to be continued with daily
dose of iron and folic acid during pregnancy. Four hundred twenty eligible subjects were enrolled
to meet approximately 115 babies born. The outcome variables were fetal survival and
concentration of serum umbilical cord IGF-1. Data were analyzed using independent t-test to
compare mean difference between MMN group and Placebo-IFA group and chi-square was used for
dichotomous data to analyzed odd ratio. Results demonstrated significant difference of fetal
survival (gestation age >37 weeks) between MMN group and Placebo-IFA group (p = 0.003). Fetuses
in MMN group were more likely  to  survive  than  those  in  Placebo-IFA group (OR = 6,099; 95%
CI: 0.934-39.847). Despite IGF-1 concentration of umbilical cord of neonates in MMN group was
higher (23.6±16.2 ng mLG1) compare to those in Placebo-IFA group (15.8±17.3 ng mLG1) but it was
not different significantly (p = 0.070). Furthermore, IGF-1 concentration of umbilical cord of male
neonates (18.3±12.2 ng mLG1) was lower than that of female neonates (21.5±19.9 ng mLG1). These
findings imply that MMN supplementation prior to pregnancy is very important to support intra
uterine environment in early pregnancy for successful complete gestation period.
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INTRODUCTION
The period of intrauterine growth and development is the most vulnerable in human life cycle.
Many studies revealed that most of the adverse  pregnancy  outcomes  such  as  fetal  loss,  preterm
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delivery and intrauterine growth restriction (IUGR) appeared as a  result  of  the  unsuccessful
fetal-maternal  communication  in  early  pregnancy,  particularly  during implantation  period
(Van Nieuwenhoven et al., 2003; Imakawa et al., 2004).
The probability of conception during one menstrual cycle is approximately 30% and only 50-60%
of all conceptions survive beyond 20 weeks of gestation. Of the pregnancy that are lost, 75% are due
to failure of implantation, before the women becomes aware that they might have been pregnant
(Wilcox et al., 1988; Macklon et al., 2002). It means that to survive during pregnancy is a hard effort
for a human conceptus, because most of conceptie loss in early pregnancy.
Miscarriage or spontaneous abortion and preterm delivery are the common adverse pregnancy
outcomes. Miscarriage occurs from 31 (Wilcox et  al., 1988) up to  50%   (El-Sayed  et al.,  2009;
Hure et al., 2012). The incidence of preterm delivery worldwide is about 9.6% globally. This rates
are various across regions from 6.2% in Europe to 9.1% in Asia, 10.6% in North America and 11.9%
in Africa (Beck et al., 2010). 
Despite many epidemiological evidences have been compiled extensively, the mechanism
underlying early embryonic loss and those contribute to several adverse pregnancy outcomes are
poorly understood. Maternal nutrition plays  a  critical  role  in  fetal  growth  and  development
(Fall et al., 2003; Wu et al., 2004), particularly micronutrient deficiencies have been associated with
significant high risk of pregnancy complication which are contributing to adverse pregnancy
outcomes (Hirschi and Keen, 2000; Keen et al., 2003).
The role of nutritional intervention during pregnancy to improve pregnancy outcomes has been
well documented (Villar et al., 2003) but maternal multi micronutrients supplementation had no
significant effect on cord hormone concentration (Roberfroid et al., 2010). Considering the critical
period of early pregnancy, particularly during implantation period, we intervention with
micronutrients only during pregnancy might be too late to prevent the adverse pregnancy
outcomes. Several studies provide evidences on the association between preconception multivitamin
use and preterm delivery (Vahratian et al., 2004; Catov et al., 2007) or preeclampsia (Bodnar et al.,
2006). 
Those evidences ensure the plausibility that micronutrients supplementation pre-conceptually
may be more important than during pregnancy itself (Shah and Sachdev, 2004) and also in
periconceptional period (Cetin et al., 2010). Based on such evidences, we investigated the efficacy
of multi-micronutrients (MMN) supplementation during preconception period on fetal survival and
fetal growth hormone, particularly Insulin-like Growth Factor 1 (IGF-1). 
MATERIALS AND METHODS
A randomized double blind community-based trial had been conducted at district of
Probolinggo, East Java province. The study protocol was approved by Ethical Committee, Faculty
of Medicine Gajah Mada University with register No. KE/FK/202/EC. The study was also registered
with register trials number TCTR20150614001. Beginning on March 2011 until July 2012, we
enrolled 420 eligible subjects from physical screening of 1603 newly married women at catchment
area of 9 selected health centers. The eligible subjects were newly married women who desired to
be pregnant in the 1st year of marriage, 16-35 years age and apparently healthy. They were
randomly assigned to received either multi micronutrient from United Nations International
Multiple Micronutrients Preparation (UNIMMAP) formulation containing 15 micronutrients, every
2 days (1 day intermittent) during preconception period and to be continued with daily dose during
pregnancy (MMN group) or  placebo  during  preconception  period  and  to  be  continued with daily
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dose of iron and folate, 60 mg  iron and 250 μg,  respectively  only  during  pregnancy (Placebo-IFA
group). Randomization had been carried out by using a random permuted blocks method with block
size of 10 and allocation ratio 1:1, then we had equal subjects of 210 in each group (Meinert and
Tonascia, 1986).
Supplements for two groups were prepared in similar physical appearance of capsules in size
and color to blind both researcher and subjects. Furthermore, MMN used the UNICEF-derived
formulation containing 15 micronutrients: 30 mg iron, 400 μg folic acid, 800 μg retinol, 200 IU
vitamin D, 10 mg vitamin E, 70 mg vitamin C, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg
vitamin B3, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 15 mg zinc, 2 mg copper, 65 μg selenium and
150 μg iodine. Package of supplement was delivered to subjects monthly in dark color bottles, each
bottle contains 16 capsules and 30 capsules for preconception and pregnancy period respectively.
Field workers were responsible to distribute supplement and monitor the adherence of supplement
consumption by home visit regularly. To monitor the adherence of supplement consumption, all
subjects received a simple monitoring card and checked the monitoring card as well as validated
by counting the remaining capsules in each bottle.
At enrollment, all newly married women who fulfilled the inclusion criteria were recruited and
signed an informed consent. Pregnancy detection was done by urinary human Chorionic
Gonadotrophin (hCG) and blood glucose test was done using rapid test kit Nesco® for diabetic
screening. Physical test was also carried out by medical doctor at women and child services unit
of health center.  Women  who  were  detected  pregnant  or  suspect  of  diabetes  (blood glucose
>200 g dLG1) and apparently unhealthy were excluded. Subjects who fulfilled the inclusion criteria
received Albendazole tablet to eliminate worm infection, before they received supplement. The
Albendazole tablet was consumed in front of field workers or midwives, during enrollment. 
The primary outcome variables were fetal survival and cord blood Insulin-like Growth Factor
1 (IGF-1). Fetal survival was reflected by gestation age and categorized as dichotomous data using
single cut off point gestation age of 37 weeks (survive if gestation age $37 weeks). Gestation age
was calculated on the basis of the last menstrual period which was noted monthly in monitoring
card. Concentration IGF-1 was assessed from venous umbilical cord blood serum. Midwives or
laboratory workers collected venous blood of umbilical cord immediately after delivery at hospital
or health center, as well as delivery at home. About 8 mL of blood was extracted from the clamped
cord with syringe, then transferred gently into a polypropylene 10 mL dry tube without
preservative and allowed it to clot at room temperature for 30-45 min. Blood sample then
centrifugated at 3000 rpm for 10 min and serum was frozen immediately at -20°C. If babies were
born at village health center or midwive’s home, cord blood was immediately delivered by a carrier
to local hospital using cold chain equipment, then centrifugated and frozen storage according to
standard procedure. The frozen serum samples  were  then  delivered  to Biomaterial Laboratory,
Dr. Soetomo General Hospital Surabaya to be stored at -80°C until ready for analysis.
Concentration of sera IGF-1 were analyzed at Clinical Pathology Laboratory Dr. Soetomo
General Hospital Surabaya, using Enzyme-linked Immunosorbent Assay (ELISA) and commercial
kit Quantikine® for human IGF-1 immunoassay, from R and D System, USA. Social economic
background, nutritional status including body mass index and mid Upper Arms Circumferences
(MUAC) were also assessed at baseline. Body weight was measured by using digital body weight
scale Seca® type 803. Height or stature was measured by using microtoise, MUAC was measured
by using fiber tape (Unicef). The overall data set was completely compiled on July 2014.
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Baseline data was statistically analyzed by using independent t-test and Mann-withney U-test
to compare mean difference between MMN group and Placebo-IFA group. Chi-square test was done
to examine the different of fetal survival between MMN group and Placebo-IFA group, as well as
to analyzed odd ratio. Independent t-test was also used to examine effect of treatment on
concentration of IGF-1 in cord blood serum. 
RESULTS
Subject enrollment: We carried out physical screening of 1603 newly married women from 9
selected sub districts. First of all, we excluded 851 subjects since they did not desire to be pregnant
in the 1st year of marriage, and/or used contraception. Then 752 subjects who desired to have a
child in the 1st year of marriage continued the next step screening. In the early selection by
midwives, 201 married women were not eligible for the next screening due to various reasons, such
as 126 subjects were pregnant based on rapid test for urinary human chorionic gonadotropin and
75 subjects moved  out  from  study  areas.  Further  step, 551 subjects got physical examination
and pregnancy test. Among them, 131 subjects were not eligible since three subjects had
tuberculosis (TB) infection, two subjects were suspected of diabetes mellitus and 126 subjects were
already pregnant. The TB infection was detected base on sputum test and subjects who suspected
diabetes were detected base on twice non fasting blood glucose test with glucose level>200 g dLG1.
Subjects who were detected getting pregnant at enrollment were not eligible because we had missed
their preconception period. Base on the screening process, we fulfilled 420 eligible subjects to be
enrolled the study (Fig. 1).
All eligible subjects were assigned randomly into two groups (MMN group and Placebo-IFA
group). In MMN group there were 95 pregnant subjects, which were 38 subjects were pregnant
before 2 months of intervention and 57 subjects were pregnant after 2 months intervention. Total
pregnant subjects in Placebo-IFA group were 106, 48 subjects getting pregnant before 2 months
intervention and 58 subjects were pregnant after 2 months intervention. Subjects who pregnant
before 2 months of intervention were not intensively followed up,  because  they  did  not received
2 months intervention prior to pregnancy. Only subjects who pregnant after received 2 months of
intervention were intensively followed up until birth. There were 56 births and 36 cord blood
samples in MMN group and 50 births and 28 cord blood samples in Placebo-IFA group. Figure 1
shows the flow chart of entire eligible subjects enrolled and randomized into two groups.
Baseline data of treatment (MMN) group and control (Placebo-IFA) group
Social economic status: The social economic status was recorded such as age, education level,
occupation, income and marital status. The data were presented descriptively and compared
between MMN group and Placebo-IFA group.
Table 1 revealed that subjects within MMN group were relatively younger than Placebo-IFA
group. The average of age within treatment group was 20.9±3.3 years, compared to 22.4±3.9 years
within control group. Subjects within MMN group were mostly younger than 20 years and in
arrange of 20-25 years with percentage of 43.9% in each age category. More than a half of subjects
within Placebo-IFA group were in  20-25  years (51.7%). Percentage  of  subject age younger than
20 years in MMN group was higher (43.9%) than in Placebo-IFA group (25.9%). 
Education level of Placebo-IFA group was relatively higher compare to MMN group. Subjects
who graduated  from university or college were higher in Placebo-IFA group (24.1%) than
treatment  group  (10.5%).  Most  of  subjects  in  two  groups  had  no occupation (housewives), with
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Fig. 1: Flow chart of research work
percentage of 68.4% within MMN group and 63.8% within Placebo-IFA group. Teacher and
industrial workers were other type of occupation with high percentage than other categories. Less
than 40% of subjects had income and more  than  half  of  subjects  within  two  groups  had  income
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Table 1: Social economic status of subjects within multi-micronutrients  and Placebo-IFA group
MMN group (n = 57) Placebo-IFA group (n = 58)
---------------------------- -------------------------------------
Variables No. % No. % Statistical analysis
Age (years) 
<20 25 43.9 15 25.9
20-25 25 43.9 30 51.7 p = 0.026
>25 7 12.3 13 22.4
Education level 
No schooling at all 1 1.8 0 0.0
Elementary school 8 14.0 9 15.5
Junior high school 13 22.8 16 27.6 p = 0.598
Senior high school 29 50.9 19 32.8
Graduate of university/collage 6 10.5 14 24.1
Occupation
No occupation 39 68.4 37 63.8
Teacher 4 7.0 12 20.7
Health practices 2 3.5 1 1.7
Civil servant 1 1.8 0 0.0 p = 0.362
Industrial worker 8 14.0 5 8.6
Others 3 5.4 3 5.1
Income
<500,000 9 50.0 13 61.9
500,000-1,000,000 5 27.8 8 38.1 p = 0.138
>1,000,000-2,000,000 3 16.7 0 0.0
>2,000,000 1 5.6 0 0.0
Marital status
1st marriage 57 1005.0 57 98.3 p = 0.322
2nd marriage 0 1 1.7
*Statistical analysis using Mann-Whitney U-test for categorical data (education, occupation and marital status), independent t-test for
age and income (α = 0.05), MMN: Multi-micronutrients
below Rp 500,000. The income level was more likely greater within MMN group rather than
Placebo-IFA group, whereas no subject within Placebo-IFA group had income up to Rp 1000,000. 
All subjects in MMN group were in the 1st marriage and 98.3% of subjects in Placebo-IFA group
also in their first marriage but only 1.7% was in second marriage.
Statistical analysis was carried out to compare the mean value between MMN group and
Placebo-IFA group to ensure the homogeneity by using independent t-test and Mann-withney U-
test for continuous data and categorical data respectively. Table 1 shows, all statistical tests
revealed that there were no significant difference of socio-economic characteristic between two
groups (p>0.05), unless for age (p = 0.026). 
Anthropometric measurement: The baseline data between MMN group and Placebo-IFA group
were compared descriptively. Some variables discussed were nutritional status including body size
such as body weight, height, as well as mid Upper Arms Circumference (MUAC). All
anthropometric data were shown in Table 2.
The preconceptional body size and nutritional status of pregnant subjects in two groups look
like similar. Table 2 shows that underweight subjects were 22.8 and 24.1% in MMN group and
Placebo-IFA group, respectively. Percentage of overweight and obese subjects was twice higher in
Placebo-IFA group (15.5%) compared to MMN group (8.8%). Subjects within Placebo-IFA group
were slightly shorter than  those  in  MMN  group. Percentage  of  subjects  with  short stature
(<145 cm) was slightly higher within Placebo-IFA groups (17.2%) than MMN group (14%).
Moreover, MUAC variable revealed that percentage of subjects with risk for chronic energy
deficiency (<23.5 cm) was more than 30% in both groups.
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Univariate analysis for mean comparison between MMN group and Placebo-IFA group was
done using independent sample t-test for homogeneity testing. All baseline anthropometric data
which reflected the initial condition or preconception data between two groups were tested, as
shown in Table 3. Results showed that no significant differences of means between two groups
(p>0.05) for all anthropometric measurement including body weight, height, MUAC, as well as
Body Mass Index (BMI). All data were comparable between two groups. 
Effect of treatment on fetal survival: Among pregnant women who were intensively followed
until delivery, there were 3 subjects loss of follow up due to they moved out from study area.
Therefore, we had 112 data of fetal survival. Table 4 shows the distribution of fetal survival data
and fetal age based on treatment group. Babies born before 37 weeks of gestation were categorized
as not-survive, consist of abortion (fetal loss before 20 weeks of gestation) and preterm delivery
(birth before 37 weeks of gestation). Either fetal loss (miscarriage) or  preterm  delivery more  likely
Table 2: Baseline of anthropometric status in multi-micronutrients and Placebo-IFA group as preconception data
MMN group (n = 57) Placebo-IFA group (n = 58)
---------------------------------------------- --------------------------------------------
Variables No. % No. %
BMI
Under weight 13 22.8 14 24.1
Normal weight 39 68.4 35 60.3
Over weight 4 7.0 7 12.1
Obese 1 1.8 2 3.4
Body weight (kg)
<40 11 19.3 10 17.2
$40 46 80.7 48 82.8
Height (cm)
<145 8 14.0 10 17.2
$145 49 86.0 48 82.8
MUAC (cm) 
<23.5 18 31.6 19 32.8
$23.5 39 68.4 39 67.2
MMN: Multi-micronutrients, BMI: Body mass index, MUAC: Mid upper arms circumference
Table 3: Univariate analysis to compare the means value of several preconception data between MMN group and Placebo-IFA group
Variables MMN group (n = 57) Placebo-IFA group (n = 58) p-value*
Body weight 47.4±8.1 47.3±9.2 0.920
Height 150.9±5.6 149.9±5.7 0.308
MUAC 25.2±3.3 25.3±3.8 0.833
BMI 20.8±3.5 21.0±3.8 0.805
*Statistical analysis using independent t test (α = 0.05), MMN: Multi-micronutrients, BMI: Body mass index, MUAC: Mid upper arms
circumference
Table 4: Distribution of fetal survival and fetal age within multi-micronutrients and Placebo-IFA group 
MMN group (n = 57) Placebo-IFA group (n = 55) Total (n = 112)
----------------------------- ------------------------------------- ------------------------------
Gestation age No. % No. % No. %
Fetal survival*
Survival ($37 weeks) 56 98.2 45 81.8 101 90.2
Not survive (<37 weeks) 1 1.8 10 18.2 11 9.8
Fetal age
Miscarriage (<28 week) 1 1.8 4 7.4 5 4.5
Early preterm (28-35 weeks) 0 0.0 4 7.4 4 3.6
Late preterm (35-37 weeks) 2 3.5 2 3.7 4 3.6
At term (>37 weeks) 54 94.7 45 81.5 99 88.4
*Chi-square test: Contingency coefficient: 0.266, p  =  0.003 (OR: 6,099, 95% CI: 0.934-39.847), MMN: Multi-micronutrients, BMI: Body
mass index, MUAC: Mid upper arms circumference
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occurred in Placebo-IFA group than in MMN group. Percentage of not-survive fetal was higher in
Placebo-IFA group (18.2%) than MMN group (1.8%). In MMN group there was only one case of
miscarriage, whereas in Placebo-IFA group there  were  miscarriage  as  well  as early preterm
(born in 28-35 weeks) 4 (7.4%) in cases each. The detailed data regarding fetal loss and preterm
delivery both of early preterm and late preterm between MMN group and Placebo-IFA group was
shown in Table 4.
Based on statistical analysis for dichotomous data using chi-square test, it revealed that there
was significant difference of fetal survival between MMN group and Placebo-IFA group, 98.2% and
81.8% respectively (p = 0.003). Fetuses in MMN group showed higher survival rate compared to
Placebo-IFA group (OR = 6,099; 95% CI: 0.934-39.847). From the Odd Ratio (OR) value, it implies
that fetuses in MMN group had six times to be survive compare to fetuses in Placebo-IFA group. 
Effect treatment on cord blood IGF-1: Out of 112 of pregnant subjects who followed up until
complete gestation, there were 107 subjects delivered their babies, with only 64 cord blood samples
collected (36 samples and 28 samples in MMN group and Placebo-IFA group, respectively).
Descriptive data of concentration of cord blood IGF-1 including mean value, standard deviation as
well as range value was shown in Table 5. Mean value of serum cord blood IGF-1 concentration was
higher in MMN group (23.6±16.2 ng mLG1) than that in Placebo-IFA group (15.8±17.3 ng mLG1).
Otherwise, statistical analysis using independent t-test revealed that there was no significant
difference of IGF-1 concentration between two groups (p = 0.070). Furthermore, IGF-1
concentration of umbilical cord of male neonates (18.3±12.2 ng mLG1) was lower than that of female
neonates (21.5±19.9 ng mLG1) but it was not significantly different (p = 0.387). Data plot of IGF-1
concentration between MMN group and Placebo-IFA group or between male and female neonates
were performed in Fig. 2 and 3, respectively. 
Table 5: Comparison of mean value of IGF-1 concentration (ng mLG1) between multi-micronutrients and Placebo-IFA group
Descriptive value MMN group (n = 36) Placebo-IFA group (n = 28) Total (n = 64)
Mean* 23.6±16.2 15.8±17.3 20.1±17.0
Range 3.3-63.7 1.5-87.1 1.5-87.1
*Independent t test : t = 1.844, df = 61, p = 0.070,  mean  difference  =  7.806,   MMN: Multi-micronutrients,  IGF-1:  Insulin-like growth
factor 1
Fig. 2: Mean comparison of serum umbilical cord IGF-1 concentration between MMN group and
Placebo-IFA group (p = 0.070)
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Fig. 3: Mean comparison of serum umbilical cord IGF-1 concentration between male and female
neonates (p = 0.387)
DISCUSSION
Fetal survival is defined as the ability of fetus to survive in uterine until delivery in complete
gestation period  or  at  term  delivery (birth >37 weeks).  Un-survive  fetus  is  fetus  loss  before
20 weeks of gestation (miscarriage) or preterm delivery. Based on data which were described
previously, it is known that miscarriage or fetal loss and early preterm were more frequent in
Placebo-IFA group rather  than  in  MMN group. Gestational  age  was  in  a  range of 10-42 and
8-43 weeks  in  MMN  group  and  Placebo-IFA  group,  respectively,  with  averages  of 38.9 and
36.6 weeks, respectively. The wide mean difference of gestational age between two groups was due
to high percentage of miscarriage (7.4%) and early preterm (7.4%) in Placebo-IFA group.
Supplementation of MMN might prolong the gestational age of subjects within group, since
several micronutrients such as selenium, zinc and vitamin D play an important role in
implantation phase. Selenium influence progesterone production (Kamada and Hodate, 1998),
furthermore, this hormone activates the receptors, exerting a tubular relaxing effect that allows
entry of the ovum into the uterus (Guyton and Hall, 2006). Zinc and its protein transport ZIP8
(SLC39A8) stimulate IFNγ expression (Aydemir et al., 2009), which plays important role in
initiation  and  modification  of  uterine  vessel  and  make  the  integrity  of   decidual  tissue
(Ashkar et al., 2000). Remodeling of spiral artery is influenced by Zinc as well, since zinc is required
by matrix metalloproteinase (Smith et al., 2009). Vitamin D 1.25(OH)2D also aids in the
transformation of endometrial cells into decidual cells and increases expression of HOXA10, a gene
important for embryo implantation in early pregnancy (Shin et al., 2010).
Vitamin C and E in MMN play important role on prevention of  preterm  delivery. Woods et al.
(2001) provide detailed explanation about the role of vitamin C and E to prevent premature rupture
of chorionic membrane and prolong  gestational  age  and  prevent  preterm delivery. Body iron
store also plays an important role in determining  the  gestation  period  via  the  role of
corticotropin-releasing hormone (Allen, 2001). 
Because of maternal growth hormone is not transferred across the placenta, the fetus is entirely
depending  on  its pituitary gland for growth hormones production. Insulin-like growth factor-1
(IGF-1) is the main important hormone  that  regulates  the  fetal  growth.  Fetal  IGF-1 
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concentration  is positively correlated with gestational age (Pirazzoli et al., 1997). Moreover, IGF-1
was regulated by glucose level, which is concentration of serum IGF-1 in fasting rat was lower than
those in non fasting rat was demonstrated in animal study conducted by Davenport et al. (1990). 
There was no significant difference in mean value of IGF-1 concentration in serum cord blood
between the two groups but the mean of IGF-1concetration in MMN group tend to be higher than
that in Placebo-IFA group. This finding was in agreement with another study conducted by
Roberfroid et al. (2010). This condition is possible since several micronutrients play important role
in synthesis of IGF-1. Besides zinc and vitamin A play an important role in cell proliferation, thus
micronutrients also stimulate synthesis of IGF-1. In animal study, it was demonstrated that
vitamin A deficiency caused decrease of plasma IGF-1 concentration and it was suggested that
possible physiologic role of the IGF system to support growth was mediated by vitamin A (Fu et al.,
2001). Furthermore, IGF-1 was also affected by zinc status and the influence of zinc status on
circulating IGF-1 concentration was independent on total energy intake (Cossack, 1986).
Such previous findings explained the detailed mechanisms how micronutrients able to influence
fetal growth and development in early pregnancy clearly support our recent finding. It imply that
our data provide the importance evidence that fetuses of women who received micronutrients
supplement prior to pregnancy have six times more probable to be survive compare to fetuses of
women who received iron folic acid only during pregnancy. 
CONCLUSION
These findings reveal that MMN supplementation prior to pregnancy is very important to
support intra uterine environment in early pregnancy for successful complete gestational age. Fetal
survival rate in MMN group was significantly higher than those in Placebo-IFA group. Moreover,
MMN supplementation prior to pregnancy also tends to increase umbilical cord serum IGF-1. 
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